Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (181-190 of 238) with videos related to

Pageof 24
Sort By:
Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
Journal of Hepatology|October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY scoreBernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registriesAlessio Cortellini, Gino M Dettorre, Urania Dafni, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registryBruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, et al.
JHEP Reports : Innovation in Hepatology|December 29, 2022
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinomaBernhard Scheiner, Daniel Roessler, Samuel Phen, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Science Translational Medicine|July 15, 2021
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancerStelios Chrysostomou, Rajat Roy, Filippo Prischi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 29, 2023
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registryAnahita Mostaghim, Samuel Minkove, Juan Aguilar-Company, et al.
Pageof 24

Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
Journal of Hepatology|October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY scoreBernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registriesAlessio Cortellini, Gino M Dettorre, Urania Dafni, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registryBruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, et al.
JHEP Reports : Innovation in Hepatology|December 29, 2022
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinomaBernhard Scheiner, Daniel Roessler, Samuel Phen, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Science Translational Medicine|July 15, 2021
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancerStelios Chrysostomou, Rajat Roy, Filippo Prischi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 29, 2023
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registryAnahita Mostaghim, Samuel Minkove, Juan Aguilar-Company, et al.
Pageof 24